Quantcast

Industry news that matters to you.  Learn more

Archives for May 2015

Edico Genome’s DRAGEN Bio-IT Processor Enhances PerkinElmer’s Next-Generation Sequencing Workflow

Edico Genome recently announced that PerkinElmer, Inc. has purchased a DRAGEN™ Bio-IT processor to expedite the analysis of its customers’ next-generation sequencing (NGS) data. Applying the processor to PerkinElmer’s NGS workflow, DRAGEN accelerates analysis time for whole genome and whole exome sequencing 60 fold, compared to standard industry software, while maintaining greater than 99 percent sensitivity. The processor will be integrated into PerkinElmer’s CLIA-certified, high-throughput sequencing facility.

iSpecimen Technology Consolidates the Procurement Process for Human Biospecimens

iSpecimen, a trusted source of customized human biospecimen collections, recently released its latest technology that connects biomedical researchers to high quality, annotated human biospecimens that would otherwise be discarded by hospitals and labs after clinical testing is complete. Through this model, researchers gain access to the specimens they need from the patients they want and healthcare providers gain a new opportunity to contribute to biomedical research while improving their bottom line.

QIAGEN Partners With World’s Largest Sequencing Provider

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently today that it has expanded its relationship with BGI, the world’s largest genomics organization, to provide QIAGEN’s Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI’s sequencing services.

Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies

Eli Lilly and Company (NYSE:LLY) and BioNTech AG recently announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.

MediSapiens Expanding Rapidly into Precision Medicine and Genomic Diagnostics

Earlier this year MediSapiens announced a joint venture with International Cancer Advocacy Network (ICAN) to develop and publish Remission Coach®, a web-based solution that addresses the urgency of cancer management.  This innovative solution provides cancer patients with a personalized platform for actively determine the most appropriate clinical trial for that patient’s disease and treatment history. Now MediSapiens announces collaboration with Genoscoper Laboratories, leading animal DNA diagnostics laboratory.